Treace Medical Concepts (TMCI) Q3 2026 earnings review
Treace Medical cuts losses and lifts volumes while revenue dips
Treace Medical Concepts, a maker of surgical bunion implants, is performing more surgeries and spending less while lower-priced kits still weigh on sales. Excluding stocking distributors, third-quarter sales grew mid-single digits on double-digit procedure growth, while reported revenue slipped 4% to $48 million. Chief executive John T. Treace cut operating expenses by 10%, turning Adjusted EBITDA positive and leaving about 7% fourth-quarter revenue growth implied by the full-year outlook.
| Sales excluding stocking distributors | +Mid-single digits reported revenue: $48.3M (-3.9% from a year ago) |
|---|---|
| Adjusted EBITDA | $0.3M loss of $2.6M a year ago |
| Lapiplasty surgeons using 2025 systems | 45% 40% last quarter |
| Full-year Adjusted EBITDA outlook | Raised $2.5M middle of the range: $1.5M loss |
⚖️ Verdict: 🟢 Bullish
The story got better because procedure volume growth stepped up to double digits and cost cuts reduced the full-year Adjusted EBITDA loss plan by $2.5 million. Surgeon adoption of the three newer bunion systems rose to 45% without hurting gross margin. One caution: cash and securities fell to $40 million, narrowing the cushion above a $36 million loan threshold as patent lawsuit bills mount.
The question now is whether the fourth-quarter return to reported sales growth will reflect genuine expansion or just an easy comparison against last year's distributor shift. If the newer kits bring extra cases, revenue growth will converge toward double-digit procedure growth; if they mostly replace higher-priced Lapiplasty kits, sales growth will lag behind after the fourth quarter. Fourth-quarter revenue above the $67 million implied by the plan will tell.
🐂 Bull Case
Cost Cuts Drove Profit Positive Ahead of Schedule
Treace Medical Concepts, a maker of surgical implants and instruments for bunions, wants to cut cash burn while growing procedure volumes. That effort moved faster than planned this quarter because operating expenses fell 10% from a year ago to $49.9 million, led by a 7.0 percentage point drop in sales and marketing costs as a share of revenue.
- Sales and marketing expense: 61.6% of revenue, down from 68.5% a year ago
- Adjusted EBITDA (operating profit before stock pay, depreciation, and lawsuit costs): positive $0.3 million, up from a $2.6 million loss a year ago
- Year-to-date cash usage: down 53%, or $9.7 million, compared to the first nine months of 2025
Because the company kept tight control through "targeted expense reduction initiatives across the organization", it trimmed its full-year Adjusted EBITDA loss forecast by $2.5 million at the middle of the range. Gross margin (profit after the cost of making the implants) also rose 0.4 percentage points to 79.5% even as sales shifted toward cheaper kits.
What to watch: fourth-quarter sales and marketing spending when full-year results arrive. If the medical device maker holds these cost savings during its busiest surgery season, full-year Adjusted EBITDA should beat the new loss range.
Surgeon Adoption and Procedure Volumes Accelerated
To reach surgeons who prefer smaller incisions over its original Lapiplasty 3D bunion system, Treace launched three newer bunion systems in late 2025 alongside SuperBite compression screws for foot fusions. Chief executive John T. Treace said these products let the US group "penetrate a much broader range of our surgeon customers’ most common foot and ankle procedures."
The company "Achieved double digit procedure volume growth in the third quarter", stepping up from high-single-digit growth in the second quarter. Around 45% of Lapiplasty surgeons now use at least one of the three newer bunion systems, up from 40% last quarter and 35% in the first quarter. Excluding sales to stocking distributors, revenue rose mid-single digits from a year ago.
What to watch: fourth-quarter revenue growth once the comparison passes last year's new product launches. If double-digit procedure volume holds without the price reset from a year ago, reported top-line growth will finally match surgical volume.
🐻 Bear Case
Cheaper Kits Still Hold Reported Sales Below Last Year
"We believe this balanced approach positions us to build momentum and deliver stronger growth to finish the year," chief executive John T. Treace said. Yet reported revenue fell 3.9% from a year ago to $48.3 million, extending a string of top-line declines that started in the fourth quarter of 2025.
The company blamed the drop on a "shift in revenue mix towards lower priced minimally invasive products and lower volume of bunion procedure kits sold." Even when stripping out stocking distributors—who bought heavily in the third quarter of 2025—revenue grew only mid-single digits while procedure volumes grew double digits. By our math, that means average revenue per procedure fell roughly 5% to 7%.
This gap matters because Treace does not disclose how much revenue comes from Lapiplasty versus the cheaper kits. If surgeons are simply swapping expensive Lapiplasty procedures for lower-priced minimally invasive kits rather than bringing new patients, revenue growth will stay well below procedure growth even after the launch anniversary passes.
What to watch: fourth-quarter revenue against the $67.2 million implied by the middle of the full-year outlook. Because last year's fourth quarter lost about $3 million of distributor orders to the third quarter, beating $67.2 million is required to prove genuine growth beyond an easy comparison.
Cash Burn Narrows Cushion Above Loan Threshold
Treace highlighted that its existing credit facility offers up to $115 million in extra borrowing capacity subject to conditions, and that nine-month cash usage fell 53%. However, cash and marketable securities dropped by $5.8 million during the third quarter to $39.8 million, down from $48.4 million at the end of 2025.
Under its loan terms, the surgical device maker must keep cash and securities above 60% of its $60 million term loan—or $36.0 million—to avoid triggering minimum revenue requirements. Meanwhile, patent lawsuit costs rose 162% from a year ago to $2.7 million in the quarter ($7.0 million year to date), with $1.7 million financed through debt that starts repayment in 2027.
What to watch: year-end cash and marketable securities on the fourth-quarter balance sheet. Because fourth-quarter sales usually build up unpaid customer bills before cash is collected, a balance below $36.0 million would put the loan's revenue rules into play.
Risks this quarter didn't answer
Three standing items from prior quarters received no update in the third-quarter earnings release and await the conference call or quarterly filing.
- Lapiplasty Lightning and Cartablaster launches: both products were slated for fourth-quarter release, but the earnings announcement did not mention their status.
- Revenue split by product line: management again withheld the sales breakdown between flagship Lapiplasty kits and the cheaper 2025 systems.
- Instrument depreciation effect: the quarterly filing will show how much of the operating loss reduction came from extending surgical instrument accounting lives from three to five years.
👓 Other Themes
Soft Consumer Sentiment Weighs on Elective Surgeries
Because bunion correction is an elective procedure that patients can delay when household budgets tighten, wider economic conditions continue to shape demand. In the release, Treace noted ongoing challenges from "lower patient demand for elective bunion surgery due to macroeconomic uncertainty and soft consumer sentiment", alongside "evolving surgeon and patient preferences for minimally invasive bunion solutions" and potential tariff or supply-chain disruptions.
💲 Other KPIs
Stock on hand rose 7.0% from last quarter and 17.4% from the end of 2025, even though reported revenue declined 3.9% from a year ago. Building inventory ahead of the busy fourth quarter is normal as Treace stocks new screw and bunion systems, but it tied up $6.3 million of operating cash over the first nine months.
Uncollected customer bills rose slightly from $28.7 million in the second quarter on higher sequential sales, but sit 28.3% below year-end 2025 and 8.3% below a year ago. Collecting bills from last winter's peak season brought in $11.6 million of operating cash over the first nine months of 2026.
The share count grew 3.1% from a year ago, matching the pace of the first two quarters. With no share buyback programme in place, employee stock grants—which cost $6.9 million, or 14.4% of revenue this quarter—steadily increase the number of shares.
🔮 Guidance
Unchanged at the middle of the range. Treace narrowed its full-year sales plan by $2 million on each end, keeping the middle at $208 million, or a 2% decline for the year. By our math, that leaves $67.2 million for the fourth quarter—up 7.4% from a year ago, reversing four straight quarters of reported declines as the company passes last year's distributor pull-forward.
Raised. Management cut its expected full-year Adjusted EBITDA loss by $2.5 million at the middle of the range, to $1.5 million, after turning a small profit in the third quarter. By our math, the new plan calls for $7.2 million of positive Adjusted EBITDA in the fourth quarter (a 10.8% margin), up from $6.2 million in the fourth quarter of 2025.
Unchanged. The foot-and-ankle group kept its target to cut full-year cash burn in half compared to the $27.3 million used in 2025. Through nine months, cash usage is down 53% (or $9.7 million), keeping the annual goal on track if fourth-quarter inventory and customer billing needs stay controlled.
❓ Key Questions
What is the revenue split between Lapiplasty and newer kits?
Procedure volumes grew double digits while revenue excluding stocking distributors grew mid-single digits. Without the sales breakdown between flagship Lapiplasty kits and cheaper minimally invasive systems, investors cannot tell how much flagship volume is moving to lower-priced kits.
Are Lapiplasty Lightning and Cartablaster still launching in Q4?
Last quarter management said both products were on track for fourth-quarter introductions, with Lapiplasty Lightning already delayed from late 2025. Neither product appeared in the third-quarter release.
Will year-end cash stay above the $36 million loan threshold?
Cash and marketable securities ended September at $39.8 million, leaving $3.8 million of room above the 60% term-loan liquidity rule before the fourth quarter's seasonal rise in uncollected customer bills.
Did Lapiplasty unit volume grow from a year ago?
Now that the third quarter has passed the one-year anniversary of the minimally invasive kit launches, knowing whether Lapiplasty procedure counts grew on their own settles whether the flagship product has stabilized.